Novel lipid-lowering therapies, including alirocumab and bempedoic acid, play pivotal roles in targeting specific parameters of lipid metabolism for the management of dyslipidemia.
What are the emerging pharmacological treatments for dyslipidemia management?
This review summarizes emerging pharmacological therapies for dyslipidemia, highlighting novel agents that target specific lipid metabolism pathways for more tailored treatment.
Dyslipidemias have emerged as prevalent disorders among patients, posing significant risks for the development and progression of cardiovascular diseases. These conditions are characterized by elevated levels of total cholesterol (TC), triglycerides (TGs), and low-density lipoprotein cholesterol (LDL-C). This review delves into the current treatment approach, focusing on equalizing these parameters while enhancing the overall quality of life for patients. Through an extensive analysis of clinical trials, we identify disorders that necessitate alternative treatment strategies, notably familial hypercholesterolemia. The primary objective of this review is to consolidate existing information concerning drugs with the potential to revolutionize dyslipidemia management significantly. Among these promising pharmaceuticals, we highlight alirocumab, bempedoic acid, antisense oligonucleotides, angiopoietin-like protein inhibitors, apolipoprotein C-III (APOC3) inhibitors, lomitapide, and cholesterol ester transfer protein (CETP) inhibitors. Our review demonstrates the pivotal roles played by each of these drugs in targeting specific parameters of lipid metabolism. We outline the future landscape of dyslipidemia treatment, envisaging a more tailored and effective therapeutic approach to address this widespread medical concern.
Dybiec et al. (Sun,) conducted a review in Dyslipidemia. Novel lipid-lowering therapies was evaluated. Novel lipid-lowering therapies, including alirocumab and bempedoic acid, play pivotal roles in targeting specific parameters of lipid metabolism for the management of dyslipidemia.